1. Schmitt J, Abraham S, Trautmann F, Stephan V, Folster-Holst R, Homey B et al (2017) Usage and effectiveness of systemic treatments in adults with severe atopic eczema: first results of the German atopic eczema registry TREATgermany. J Dtsch Dermatol Ges 15(1):49–59
2. Werfel T, Heratizadeh A, Aberer W, Ahrens F, Augustin M, Biedermann T et al (2021) Aktualisierung „Systemtherapie bei Neurodermitis“ zur S2k-Leitlinie Neurodermitis. J Dtsch Dermatol Ges 19(1):151–169
3. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF et al (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378(26):2486–2496
4. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394(10209):1638–1650
5. Nast A, Amelunxen L, Augustin M, Boehncke WH, Dressler C, Gaskins M et al (2018) S3 guideline for the treatment of psoriasis vulgaris, update—short version part 1—systemic treatment. J Dtsch Dermatol Ges 16(5):645–669